

CHEMISTRY

A EUROPEAN JOURNAL

Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007

Total Synthesis and Selective Activity of a New Class of Conformationally- Restrained Epothilones

Mamoun M. Alhamadsheh, Shuchi Gupta, Richard A. Hudson, Lalith Perera and L. M. Viranga
Tillekeratne*^[a]

[a] Department of Medicinal and Biological Chemistry, University of Toledo, Toledo, OH 43606, (USA)

Fax: (+1) 419 530-7946

E-mail: ltillek@utnet.utoledo.edu

Contents

General Methods	S2
Synthesis of Intermediates 3 and 4	S4
¹ H and ¹³ C NMR spectra for all compounds	S7
Antitumor Activity for 1b	S37
References for SI	S40

General methods.

All reactions were carried out under an argon or nitrogen atmosphere using dry solvents under anhydrous conditions, unless otherwise noted. Tetrahydrofuran (THF) and diethyl ether were distilled under nitrogen from sodium-benzophenone. The solvents used were ACS grade from Fisher. Yields refer to chromatographically and spectroscopically (¹H NMR) homogeneous materials, unless otherwise noted. Reagents were purchased from Aldrich and Acros, and used without further purification. Amano PS-D lipase was generously provided from Amano Enzyme USA. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.20 mm POLYGRAM[®] SIL silica gel plates (Art.-Nr. 805 023) with fluorescent indicator UV₂₅₄ using UV light and 15% sulfuric acid in ethanol solution and heat as visualizing agents. Normal phase flash column chromatography was carried out using Davisil[®] silica gel (100-200 mesh, Fisher). Preparative thin-layer chromatography (PTLC) separations were carried out on 1 mm, or 2 mm E. Merck silica gel plates (60F-254). NMR spectra were recorded on Varian INOVA 600, Varian VXRS-400, Bruker AC-F 300 MHz, or Nicolet NM-500 MHz (modified with a Tecmag Libra interface) instruments and calibrated using residual undeuterated solvent as internal reference. Coupling constants (*J*) were expressed in Hertz. Attached proton tests (APT) were performed to distinguish between different carbons in the ¹³C NMR spectra. The following abbreviations were used to explain the

multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and b = broad. Optical rotations were recorded on an AUTOPOL[®] III 589/546 polarimeter. High-resolution mass spectra (HRMS) were recorded on a Micromass LCT Electrospray mass spectrometer performed at the Mass Spectrometry & Proteomics Facility (The Ohio State University). (+)-Allyldiisopinocampheylborane solution in pentane was prepared by an adaptation of a procedure reported by Brown *et al.*^[1] Allylmagnesium bromide (5.82 ml of 1 M solution in ether, 5.82 mmol) was added dropwise to a well-stirred solution of (-)-*B*-methoxydiisopinocampheylborane (1.92 g, 6.062 mmol) in ether (35 ml) at 0 °C. After addition was complete, the reaction mixture was stirred at room temperature for 1h, and the solvents were pumped off under reduced pressure. The residue was extracted with dry pentane (3 x 13 ml) under nitrogen, and the stirring was discontinued to allow the precipitation of the MgBr(OMe) salt. The clear pentane supernatant was cannulated into another flask through a filtering funnel, and used without further purification.

Zinc borohydride (0.3 M solution in dry ether) was prepared by addition of saturated solution of anhydrous zinc chloride (12 g, 88.05 mmol, oven dried at 130 °C for 8 h under vacuo) in ether (50 ml) to NaBH₄ (8.1 g) in ether (150 ml).^[2,3]

General procedure for Mosher Ester: To a stirred solution of alcohol (1 equiv), DMAP (0.5 equiv), and triethylamine (3 equiv) in methylene chloride was added (*S*)-(+)- or (*R*)-(-)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride (MTPACl) (3 equiv) at room temperature. The resulting mixture was stirred overnight. The solution was diluted with ethyl acetate and washed with water, dried, and concentrated in vacuo. Purification by silica gel column chromatography will furnish the Mosher Ester.

6-Methyl-hept-6-enoic acid (7): *n*BuLi (10.8 ml of 2.5 M in hexanes, 27 mmol, 1.3 equiv) was added to a solution of methyltriphenylphosphonium bromide (9.7 g, 27 mmol, 1.3 equiv) in dimethyl sulfoxide (50 ml) at 0°C, and the mixture was stirred at room temperature for 1 h. It was then added to a solution of 6-oxo-heptanoic acid **6** (3 g, 20.82 mmol, 1 equiv) and *n*BuLi (8.33 ml of 2.5 M in hexanes, 20.82 mmol, 1 equiv) in THF (30 ml). The mixture was stirred at room temperature for 48 hr. Water was added and the mixture was acidified with 2 N HCl and extracted with methylene chloride (3 x 50 ml). The organic layer was washed with 10% aqueous sodium hydroxide solution. The aqueous layer was acidified with 2 N HCl and extracted with ethyl acetate (3 x 60 ml). The organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Purification by flash column chromatography (10% EtOAc/hexanes) gave pure acid **7** (2.32 g, 78%) as a colorless oil: TLC R_f = 0.47 (silica gel, 25% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.69 (s, 1H), 4.65 (s, 1H), 2.34 (t, J = 7.8 Hz, 2H), 2.01 (t, J = 7.8 Hz, 2H), 1.69 (s, 3H), 1.64–1.58 (m, 2H), 1.50–1.44 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 180.7, 145.6, 110.4, 37.5, 34.2, 27.1, 24.4, 22.5.

6-Methyl-hept-6-enoyl chloride (8): To a solution of the carboxylic acid **7** (2.2 g, 15.5 mmol) in benzene (30 ml), was added oxalyl chloride (3 ml, 34.4 mmol, 2.22 equiv). A drying tube was placed on the flask and the reaction mixture was stirred for 90 min at room temperature before it was concentrated in vacuo. The crude acid chloride **8** was used in the next step without further purification: TLC R_f = 0.37 (silica gel, 25% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.69 (s, 1H), 4.67 (s, 1H), 2.88 (t, J = 7.8 Hz, 2H), 2.02 (t, J = 7.8 Hz, 2H), 1.74–1.66 (m, 2H), 1.69 (s, 3H), 1.58–1.46 (m, 2H); ^{13}C NMR

(100 MHz, CDCl₃) δ 173.9, 145.1, 110.7, 46.7, 37.3, 26.4, 24.8, 22.4.

(4S)-4-Isopropyl-3-(6-methyl-hept-6-enoyl)-oxazolidin-2-one (9):

To a solution of (*S*)-4-isopropyl-2-oxazolidonone (1.56 g, 12.1 mmol, 1 equiv) in THF (40 ml) at -78°C was added *n*BuLi (4.84 ml of a 2.5 M solution in hexanes, 12.1 mmol, 1 equiv). After 15 min acid chloride **8** (2.14 g, 13.3 mmol, 1.1 equiv) was added and the mixture was stirred for 30 min at -78°C and for 15 min at 0°C. Saturated aqueous ammonium chloride solution (10 ml) was added and the resulting slurry was concentrated in vacuo. The residue was diluted with ether and washed successively with saturated aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification by flash chromatography (10% EtOAc/hexanes) gave imide **9** (2.94 g, 96%) as a colorless oil: $[\alpha]_D^{22} = +66.7$ ($c = 0.6$, CHCl₃); TLC $R_f = 0.40$ (silica gel, 25% EtOAc/hexanes); ¹H NMR (600 MHz, CDCl₃) δ 4.68 (s, 1H), 4.66 (s, 1H), 4.43-4.40 (m, 1H), 4.25 (t, $J = 9.0$ Hz, 1H), 4.19 (dd, $J = 3.0$ Hz, 9.0 Hz, 1H), 3.01-2.83 (m, 2H), 2.38-2.32 (m, 1H), 2.02 (t, $J = 7.8$ Hz, 2H), 1.69 (s, 3H), 1.67-1.61 (m, 2H), 1.51-1.46 (m, 2H), 0.90 (d, $J = 7.2$ Hz, 3H), 0.85 (d, $J = 7.2$ Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 154.3, 145.8, 110.2, 63.6, 58.6, 37.7, 35.6, 28.6, 27.2, 24.3, 22.6, 18.2, 14.9; HRMS (ESI): m/z : calcd for C₁₄H₂₃NO₃ + Na⁺ 276.1576; found 276.1567 [M + Na⁺].



(2S)-2,6-Dimethyl-hept-6-enal (3): As reported by Schinzer *et al.*^[41]: $[\alpha]_D^{22} = +11.8$ ($c = 0.5$, CHCl₃); TLC $R_f = 0.64$ (silica gel, 25% EtOAc/hexanes); ¹H NMR (600 MHz, CDCl₃) δ 9.56 (d, $J = 1.8$ Hz, 1H), 4.66 (s, 1H), 4.62 (s, 1H), 2.34-2.28 (m, 1H), 1.98 (t, $J = 7.8$ Hz, 2H), 1.69-1.62 (m, 4H), 1.48-1.27 (m, 3H), 1.05 (d,



$J = 6.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 205.3, 145.4, 110.4, 46.4, 37.8, 30.2, 24.9, 22.4, 13.5.

(5S)-5,7-Bis-(tert-butyl-dimethyl-silanyloxy)-4,4-dimethyl-

heptan-3-one (4): Sodium borohydride (570 mg, 15.4 mmol, 2 equiv) was dissolved in methylene chloride (175 ml) and dry ethanol (75 ml). The mixture was cooled to -78°C for 15 min after which a solution of aldehyde **10** ^[5] (2.2 g, 7.7 mmol, 1 equiv) in methylene chloride (5 ml) was added. After stirring for 1 h water (6 ml) was added and the reaction mixture was allowed to warm to room temperature. Methylene chloride (400 ml) was added and the mixture was washed with saturated aqueous sodium bicarbonate before it was dried over anhydrous sodium sulfate and concentrated in vacuo to give crude alcohol mixture **11** and **12**. The crude alcohol mixture was dissolved in methylene chloride (40 ml) and cooled to 0°C . Imidazole (3.14 g, 46.15 mmol, 6 equiv) and *tert*-butyldimethylsilyl chloride (3.47 g, 23.1 mmol, 3 equiv) were added and the reaction mixture was stirred at room temperature for 16 hr. Saturated aqueous ammonium chloride (30 ml) was added and the layers were separated. The aqueous layer was further extracted with ethyl acetate (3 x 30) and combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Purification by flash chromatography (1% - 5% EtOAc/Hexanes) gave the bis(silylether) **4** (2.5 g, 81% over two steps) as a colorless oil: $[\alpha]_D^{22} = -7.4$ ($c = 1.8$, CHCl_3); TLC $R_f = 0.70$ (silica gel, 20% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.06 (dd, $J = 7.6$ Hz, 3.0 Hz, 1H), 3.62-3.54 (m, 2H), 2.57-2.41 (m, 2H), 1.56-1.42 (m, 2H), 1.09 (s, 3H), 1.02 (s, 3H), 0.99 (t, $J = 7.0$ Hz, 3H), 0.86 (s, 9H), 0.85 (s, 9H), 0.07 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H), 0.002 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 215.8, 73.6, 60.3, 53.2, 37.5, 31.8, 26.3, 26.1, 22.4, 20.2, 18.5, 18.4, 7.9, -3.8,

-5.1; HRMS (ESI): m/z : calcd for $C_{21}H_{46}O_3Si_2 + Na^+$ 425.2883; found 425.2885 $[M + Na^+]$.







STANDARD PROTON PARAMETERS

Jun 14 2004



Pulse Sequence: zgpg30
 Solvent: CDCl3
 Ambient temperature
 INOVA-600 "Inova600"
 Relax. delay 1.000 sec
 Pulse 20.4 degrees
 Acq. time 3.000 sec
 Width 6590.0 Hz
 48 repetitions
 OBSERVE F1: 500.132140 MHz
 DATA PROCESSING
 Line broadening 0.4 Hz
 FT size 131072
 Total time 4 min, 18 sec



13C OBSERVE



Jun 15 2004

Pulse Sequence: zgpg30
 Solvent: CDCl3
 Ambient temperature
 UNITY-400 "Versa400"
 PULSE SEQUENCE: zgpg30
 Relax. delay 4.000 sec
 1st pulse 100.0 degrees
 2nd pulse 30.0 degrees
 Acq. time 1.200 sec
 Width 27132.0 Hz
 1968 repetitions
 OBSERVE G13: 100.6271512 MHz
 DECOUPLE H1: 200.8511841 MHz
 High power 55
 On during acquisition
 WALTZ-16 modulated
 DATA PROCESSING
 Line broadening 0.5 Hz
 Gauss window 0.500 sec
 center at 0.100 sec
 FT size 131072
 Total time 2 hr, 51 min, 30 sec



STANDARD PROTON PARAMETERS



Pulse Sequence: zgpg30
 Solvent: CDCl3
 Ambient temperature
 INOVA-500 "Inova500"
 Relax. delay 1.000 sec
 Pulse 20.4 degrees
 Acq. time 3.000 sec
 Width 6000.0 Hz
 16 repetitions
 OBSERVE H1, 500.13146 MHz
 DATA PROCESSING
 Line broadening 0.4 Hz
 FT size 131072
 Total time 1.01h, 4.00 sec



13C OBSERVE


Jun 23 2004

Pulse Sequence: zgpg30
 Solvent: CDCl3
 Ambient temperature
 UNITY-400 "Unity400"
 PULSE SEQUENCE: zgpg30
 Relax. delay 4.000 sec
 1st pulse 180.0 degrees
 2nd pulse 90.0 degrees
 Acq. time 1.200 sec
 Width 27192.4 Hz
 60 repetitions
 OBSERVE C13, 100.5671512 MHz
 DECOUPLE H1, 99.9511941 MHz
 High power 50
 on during acquisition
 VOLTAGE-16 modulated
 DATA PROCESSING
 Line broadening 0.5 Hz
 Gauss window 0.500 sec
 Center at 0.100 sec
 FT size 131072
 Total time 5.01h, 50.00 sec



```
Pulse Sequence: zgpg30
Solvent: CDCl3
Ambient temperature
INOVA-600 "inova600"



Relax. delay 1.000 sec
Pulse 26.4 degrees
Acq. time 3.350 sec
Width 8000.0 Hz
16 repetitions
OBSERVE H1 599.8723148 MHz
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131072
Total time 1 min. 4 sec
```

CC(=O)[C@H](C)[C@@H](CO[Si](C)(C)C)CC[O][Si](C)(C)C

Jun 11 2004



```
Pulse Sequence: apt
Solvent: CDC13
Ambient temperature
UNITY-400 "vyr400"

PULSE SEQUENCE: apt
Relax. delay 4.000 sec
1st pulse 160.9 degrees
2nd pulse 39.5 degrees
Acq. time 1.295 sec
Width 27192.4 Hz
352 repetitions
OBSERVE C13, 100.5671512 MHz
DECOUPLE H1 395.8511541 MHz
High power 50
on during acquisition
VALTZ-16 modulated
DATA PROCESSING
Line broadening 0.5 Hz
Gauss window 0.800 sec
cent at 0.190 sec
FT size 131972
Total time 38 min, 42 sec
```





STANDARD PROTON PARAMETERS



Pulse Sequence: s2pul
Solvent: CDCl3
Ambient temperature
File: AldolForMetathesis
INOVA-600 "Inova600"
Relax. delay 1.000 sec
Pulse 20.4 degrees
Acq. time 3.000 sec
Width 8000.0 Hz
16 repetitions
OBSERVE H1, 500.8723148 MHz
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131072
Total time 1 min, 4 sec





13C OBSERVE

Pulse Sequence: apf
Solvent: CDCl3
Ambient temperature
UNITY-100 "uxrs488"
PULSE SEQUENCE: apf
Relax. delay 4.000 sec
1st pulse 160.0 degrees
2nd pulse 39.0 degrees
Acq. time 1.200 sec
Width 27102.4 Hz
640 repetitions
OBSERVE C13, 100.5673112 MHz
DECOUPLE H1, 399.951041 MHz
High power 50
on during acquisition
VALTZ-16 modulated
DATA PROCESSING
Line broadening 2.5 Hz
Gauss window 0.500 sec
center at 0.100 sec
FT size 131072
Total time 35 min, 40 sec







STANDARD PROTON PARAMETERS
Pulse Sequence: s2pu1
Solvent: CDCl3
Ambient temperature
INNOVA-500 "Inova500"
Relax. delay 1.000 sec
Pulse 20.4 degrees
Acq. time 3.000 sec
Width 6550.0 Hz
16 repetitions
OBSERVE H1, 500.0723145 MHz
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131072
Total time 1 min, 4 sec







STANDARD PROTON PARAMETERS
Pulse Sequence: s2pu1
Solvent: CDCl3
Ambient temperature
File: PinnickoMetathesis
INNOVA-500 "Inova500"
Relax. delay 1.000 sec
Pulse 20.4 degrees
Acq. time 3.000 sec
Width 6550.0 Hz
16 repetitions
OBSERVE H1, 500.0723145 MHz
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131072
Total time 1 min, 4 sec






13C OBSERVE



Jun 18 2004


Pulse Sequence: apt
Solvent: CDCl3
Ambient temperature
UNIT: 400 MHz
PULSE SEQUENCE: apt
Relax, delay 4.000 sec
1st pulse 160.0 degrees
2nd pulse 30.0 degrees
Acq. time 1.205 sec
Width 27182.4 Hz
540 repetitions
OBSERVE C13, 100.6271512 MHz
DECOUPLE H1, 399.9511041 MHz
High power 50
on during acquisition
VOLTAGE modulated
DATA PROCESSING
Line broadening 0.5 Hz
Gauss window 0.500 sec
Center at 0.100 sec
FT size 131072
Total time 48 min, 50 sec
















Apr 17 2003







Apr 22 2013









13C OBSERVE



Pulse Sequence: apt
Solvent: CDCl3
Ambient Temperature
UNITY-400 "vnr400"
Pulse Sequence: apt
Relax. delay 4.000 sec
1st pulse 100.0 degrees
2nd pulse 39.0 degrees
Acq. time 1.295 sec
Width 27192.4 Hz
of repetitions
OBSERVE C13, 100.5671517 MHz
DECOUPLE H1, 250.8311941 MHz
High power 10
on during acquisition
WALTZ-16 modulated
DATA PROCESSING
Line broadening 2.5 Hz
Gauss window 0.568 sec
center at 9.169 sec
FT size 32768
Total time 8 min, 50 sec





Nov 29 2004











13C OBSERVE

Jul 12 2004



Pulse Sequence: apt
Solvent: CDCl3
Ambient Temperature
UNITY-600 "Ver400"
PULSE SEQUENCE: apt
Relax. delay 4.000 sec
1st pulse 135.0 degrees
2nd pulse 39.0 degrees
Acq. time 1.265 sec
Width 27192.4 Hz
8344 repetitions
OBSERVE C13, 100.6271512 MHz
DECOUPLE H1, 399.8511041 MHz
High power 50
on during acquisition
VOLT2-16 modeled
DATA PROCESSING
Line broadening 0.5 Hz
Saves window 0.500 sec
center at 0.100 sec
FT size 131072
Total time 13 hr, 9 sec



STANDARD PROTON PARAMETERS

Jun 28 2004



Pulse Sequence: szpul
Solvent: CDCl3
Ambient Temperature
INOVA-600 "Inova600"
Relax. delay 1.000 sec
Pulse 20.4 degrees
Acq. time 3.099 sec
Width 8899.5 Hz
16 repetitions
OBSERVE H1, 599.8723148 MHz
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131072
Total time 1 min, 4 sec





13C OBSERVE



Jun 29 2004



Pulse Sequence: apt
Solvent: CDCl3
Ambient temperature
UNITY-400 "var400"
Pulse Sequence: apt
Relax. delay: 4.000 sec
1st pulse 180.0 degrees
2nd pulse 90.0 degrees
Acq. Time 1.205 sec
Width 27192.4 Hz
400 repetitions
OBSERVE C13, 100.5071512 MHz
DECOUPLE H1, 200.9511941 MHz
High power 50
On during acquisition
WALTZ-16 modulated
DATA PROCESSING
Line broadening 0.5 Hz
Gauss window 0.500 sec
center at 0.100 sec
FT size 133172
Total Time 30 min, 53 sec





May 10 2005











AUG 21 2004

```
Pulse Sequence: apf
Solvent: cdcl3
Ambient temperature
UNITY410 "vxs400"



Relax. delay 4.000 sec
1st pulse 160.0 degrees
2nd pulse 39.0 degrees
Acq. len 1.185 sec
Width 2719.4 Hz
DS250 repetitions
DDECRV CL3, 198.5671511 MHz
DECOUPL 1, 198.9511041 MHz
High power on
on during acquisition
WH17-16 modulated
DATA PROCESSING
Line broadening 0.5 Hz
Gauss window 0.500 sec
Center at 6.198 sec
FT size 131072
Total time 145 hr 23 min 46 sec
```







STANDARD PROTON PARAMETERS

```
Pulse Sequence: szpul
Solvent: CDCl3
Ambient temperature
File: f1xallower
INOVA-600 "inova600"

Relax: Delay 1.000 sec
Pulst 25.4 degrees
Acq. time 3.000 sec
Width 8000.6 Hz
256 repetitions
USCVR 1 1 595.6723148 MHz
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131872
Total time 42 min, 45 sec
```











Figure 1S. Cytotoxicity data for compound **1b** against the NCI in vitro 60 cell line human tumor screen (Dose Response curves).





Figure 2S. Cytotoxicity data for compound **1b** against the NCI in vitro 60 cell line human tumor screen (In-Vitro Activity).

National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results																
NSC : D - 742992 / 1			Experiment ID : 0610NS24						Test Type : 08			Units : Molar				
Report Date : December 29, 2006			Test Date : October 16, 2006						QNS :			MC :				
COMI : MA-3 (54947)			Stain Reagent : SRB Dual-Pass Related						SSPL : 0SHE							
Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration						Percent Growth					GI50	TGI	LC50
			-8.8	-7.8	-6.8	-5.8	-4.8	-8.8	-7.8	-6.8	-5.8	-4.8				
Leukemia																
CCRF-CEM	0.207	0.904	0.819	0.082	0.131	0.111	0.299	88	-60	-37	-47	13	2.70E-9			
HL-60(TB)	0.331	1.505	1.539	1.361	1.054	0.652	0.571	103	88	62	27	20	3.27E-7	> 1.50E-5	> 1.50E-5	
K-562	0.154	1.069	1.095	1.054	1.023	0.913	0.388	103	98	95	83	26	5.62E-6	> 1.50E-5	> 1.50E-5	
RPMI-8226	0.889	2.412	2.098	2.176	2.005	2.154	1.769	79	84	73	83	58	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SR	0.149	0.443	0.326	0.219	0.177	0.135	0.074	60	24	9	-10	-51	2.85E-9	4.64E-7	1.44E-5	
Non-Small Cell Lung Cancer																
A549(ATCC	0.472	2.076	2.199	2.251	2.211	2.208	1.906	108	111	108	108	89	> 1.50E-5	> 1.50E-5	> 1.50E-5	
EKVX	0.446	1.187	1.198	1.250	1.275	1.282	1.004	102	109	112	113	75	> 1.50E-5	> 1.50E-5	> 1.50E-5	
HOP-62	0.534	1.631	1.649	1.568	1.527	1.539	1.417	102	94	91	92	80	> 1.50E-5	> 1.50E-5	> 1.50E-5	
HOP-92	0.626	0.934	0.928	0.889	0.888	0.874	0.833	98	85	85	81	67	> 1.50E-5	> 1.50E-5	> 1.50E-5	
NCI-H226	0.841	1.926	1.983	2.011	1.997	2.073	1.763	105	108	107	114	85	> 1.50E-5	> 1.50E-5	> 1.50E-5	
NCI-H23	0.442	1.183	1.154	1.208	1.375	1.177	1.035	96	103	126	99	80	> 1.50E-5	> 1.50E-5	> 1.50E-5	
NCI-H322M	0.521	1.213	1.215	1.239	1.193	1.270	1.160	100	104	97	108	92	> 1.50E-5	> 1.50E-5	> 1.50E-5	
NCI-H460	0.309	2.133	2.208	2.210	2.238	2.276	2.163	104	104	106	108	102	> 1.50E-5	> 1.50E-5	> 1.50E-5	
NCI-H522	0.716	1.624	1.568	1.490	1.588	1.543	1.232	94	85	96	91	57	> 1.50E-5	> 1.50E-5	> 1.50E-5	
Colon Cancer																
COLO 205	0.290	0.741	0.735	0.683	0.658	0.638	0.436	99	87	82	77	32	6.04E-6	> 1.50E-5	> 1.50E-5	
HCC-2998	0.639	0.997	0.919	0.988	0.899	0.939	0.780	78	97	72	84	39	8.59E-6	> 1.50E-5	> 1.50E-5	
HCT-116	0.148	1.472	1.318	1.472	1.369	1.445	0.867	88	100	92	98	54	> 1.50E-5	> 1.50E-5	> 1.50E-5	
HCT-15	0.214	1.956	2.011	1.959	1.916	1.920	1.720	103	100	98	98	86	> 1.50E-5	> 1.50E-5	> 1.50E-5	
HT29	0.213	1.227	1.157	1.191	1.219	1.211	1.083	93	96	99	98	86	> 1.50E-5	> 1.50E-5	> 1.50E-5	
KM12	0.447	1.511	1.567	1.587	1.709	1.601	1.577	105	107	119	109	106	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SW-620	0.202	1.415	1.474	1.403	1.332	1.839	1.175	105	99	93	135	80	> 1.50E-5	> 1.50E-5	> 1.50E-5	
CNS Cancer																
SF-268	0.466	1.504	1.542	1.465	1.456	1.482	1.382	104	96	95	98	88	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SF-295	0.605	2.223	2.276	2.178	2.074	2.152	2.079	103	97	91	96	91	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SF-539	0.542	1.561	1.617	1.679	1.593	1.644	1.699	106	112	103	108	114	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SNB-19	0.795	2.866	2.782	2.607	2.487	2.503	2.167	96	87	82	82	66	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SNB-75	0.270	0.561	0.571	0.584	0.562	0.563	0.506	103	108	100	101	81	> 1.50E-5	> 1.50E-5	> 1.50E-5	
U251	0.332	1.811	1.899	1.897	1.860	1.893	1.818	106	106	103	106	100	> 1.50E-5	> 1.50E-5	> 1.50E-5	
Melanoma																
LOX IMVI	0.301	2.263	2.343	2.235	2.236	2.249	2.104	104	99	99	99	92	> 1.50E-5	> 1.50E-5	> 1.50E-5	
MALME-3M	0.528	0.862	0.862	0.856	0.895	0.832	0.777	100	98	110	91	74	> 1.50E-5	> 1.50E-5	> 1.50E-5	
M14	0.348	1.374	1.229	1.341	1.270	1.324	1.259	86	97	90	95	89	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SK-MEL-2	0.581	1.134	1.181	1.148	1.159	1.116	1.116	108	103	104	97	97	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SK-MEL-28	0.373	1.118	1.138	1.132	1.101	1.086	0.975	103	102	98	96	81	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SK-MEL-5	0.290	1.310	1.378	1.416	1.286	1.304	1.084	107	110	98	99	78	> 1.50E-5	> 1.50E-5	> 1.50E-5	
UACC-257	0.929	1.958	2.021	2.098	2.014	2.006	1.840	106	114	105	105	89	> 1.50E-5	> 1.50E-5	> 1.50E-5	
UACC-62	0.720	2.330	2.359	2.465	2.424	2.530	2.104	102	108	106	112	86	> 1.50E-5	> 1.50E-5	> 1.50E-5	
Ovarian Cancer																
IGROV1	0.287	1.016	1.054	0.994	0.929	1.026	0.611	105	97	88	101	44	1.20E-5	> 1.50E-5	> 1.50E-5	
OVCAR-3	0.373	1.555	1.529	1.442	1.343	1.479	1.042	98	90	82	94	57	> 1.50E-5	> 1.50E-5	> 1.50E-5	
OVCAR-4	0.362	0.861	0.881	0.918	0.901	0.915	0.719	104	111	108	111	72	> 1.50E-5	> 1.50E-5	> 1.50E-5	
OVCAR-5	0.771	2.104	2.084	2.022	1.989	1.955	1.652	98	94	91	89	66	> 1.50E-5	> 1.50E-5	> 1.50E-5	
OVCAR-8	0.429	1.713	1.762	1.842	1.852	1.808	1.651	104	110	111	107	95	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SK-OV-3	0.753	1.202	1.192	1.170	1.184	1.168	1.139	98	93	96	92	86	> 1.50E-5	> 1.50E-5	> 1.50E-5	
Renal Cancer																
786-O	0.659	2.611	2.633	2.489	2.553	2.625	2.526	101	94	97	101	96	> 1.50E-5	> 1.50E-5	> 1.50E-5	
A498	0.845	1.453	1.454	1.466	1.457	1.442	1.403	100	102	101	98	92	> 1.50E-5	> 1.50E-5	> 1.50E-5	
ACHN	0.332	1.741	1.726	1.741	1.726	1.713	1.528	99	100	99	98	85	> 1.50E-5	> 1.50E-5	> 1.50E-5	
CAKI-1	0.640	1.769	1.820	1.655	1.617	1.732	1.294	104	90	87	97	58	> 1.50E-5	> 1.50E-5	> 1.50E-5	
RXF 393	0.828	1.403	1.429	1.378	1.436	1.393	1.303	105	96	106	98	83	> 1.50E-5	> 1.50E-5	> 1.50E-5	
SN12C	0.445	1.524	1.621	1.640	1.692	1.659	1.524	109	111	115	112	100	> 1.50E-5	> 1.50E-5	> 1.50E-5	
TK-10	0.609	1.096	1.163	1.191	1.195	1.209	1.134	114	120	120	123	108	> 1.50E-5	> 1.50E-5	> 1.50E-5	
UO-31	0.288	1.336	1.344	1.269	1.264	1.218	0.973	101	94	93	89	65	> 1.50E-5	> 1.50E-5	> 1.50E-5	
Prostate Cancer																
PC-3	0.265	1.012	1.078	0.994	1.006	0.961	0.855	109	97	99	93	79	> 1.50E-5	> 1.50E-5	> 1.50E-5	
DU-145	0.190	0.782	0.809	0.815	0.792	0.805	0.733	105	106	102	104	92	> 1.50E-5	> 1.50E-5	> 1.50E-5	
Breast Cancer																
MCF7	0.386	1.418	1.319	1.353	1.426	1.537	0.939	90	94	101	112	54	> 1.50E-5	> 1.50E-5	> 1.50E-5	
NCI/ADR-RES	0.366	1.174	1.201	1.157	1.105	1.102	0.995	103	98	91	91	78	> 1.50E-5	> 1.50E-5	> 1.50E-5	
MDA-MB-231/ATCC	0.644	1.435	1.494	1.446	1.453	1.524	1.382	107	101	102	111	93	> 1.50E-5	> 1.50E-5	> 1.50E-5	
HS 578T	0.381	0.819	0.784	0.799	0.762	0.793	0.722	92	96	87	94	78	> 1.50E-5	> 1.50E-5	> 1.50E-5	
MDA-MB-435	0.481	2.297	2.260	2.383	2.259	2.512	2.303	98	105	98	112	100	> 1.50E-5	> 1.50E-5	> 1.50E-5	
BT-549	0.635	1.222	1.293	1.315	1.321	1.322	1.229	112	116	117	117	101	> 1.50E-5	> 1.50E-5	> 1.50E-5	
T-47D	0.609	1.055	1.123	1.081	1.055	1.035	0.768	115	106	100	96	36	8.65E-6	> 1.50E-5	> 1.50E-5	



SI References:

- [1] P. K. Jadhav, K. S. Bhat, P. T. Perumal, H. C. Brown, *J. Org. Chem.* **1986**, *51*, 432-439.
- [2] W. J. Gensler, F. Johnson, A. Sloan, *J. Am. Chem. Soc* **1960**, *82*, 6074-6081.
- [3] D. V. Patel, F. VanMiddlesworth, J. Donaubauer, C. Sih, *J. Am. Chem. Soc.* **1986**, *108*, 4603-4614.
- [4] D. Schinzer, A. Bauer, J. Schieber, *Chem. Eur. J.* **1999**, *5*, 2492-2500.
- [5] K. C. Nicolaou, S. Ninkovic, F. Sarabia, D. Vourloumis, Y. He, H. Vallberg, M. R. Finlay, Z. Yang, *J. Am. Chem. Soc.* **1997**, *119*, 7974-7991.